Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV

Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers

(2015) Pablo Tebas et al.   AIDS

Modeling and Simulation Approach to Support Dosing and Study Design Requirements for Treating HIV-Related Neuropsychiatric Disease with the NK1-R Antagonist Aprepitant

(2014) Jeffrey Barrett et al.   CURRENT HIV RESEARCH

Efavirenz modulation of sleep spindles and sleep spectral profile

(2014) Arthur A. Simen et al.   JOURNAL OF SLEEP RESEARCH

Adjuvant therapies for HIV-associated neurocognitive disorders

(2014) Jennifer L. McGuire et al.   Annals of Clinical and Translational Neurology

The HIV Antiretroviral Drug Efavirenz has LSD-Like Properties

(2013) Michael B Gatch et al.   NEUROPSYCHOPHARMACOLOGY

Efficacy of Vestipitant, A Neurokinin-1 Receptor Antagonist, in Primary Insomnia

(2013) Emiliangelo Ratti et al.   SLEEP

Inclusion complex of aprepitant with cyclodextrin: evaluation of physico-chemical and pharmacokinetic properties

(2012) Devendra N. Ridhurkar et al.   DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY

Plasma IL-6 and IL-9 predict the failure of interferon-  plus ribavirin therapy in HIV/HCV-coinfected patients

(2012) M. Guzman-Fulgencio et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

HIV and Inflammation: Mechanisms and Consequences

(2012) Peter W. Hunt   Current HIV/AIDS Reports

Results From 2 Randomized, Double-Blind, Placebo-Controlled Studies of the Novel NK1 Receptor Antagonist Casopitant in Patients With Major Depressive Disorder

(2011) Emiliangelo Ratti et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A Randomized, Placebo Controlled, Double Masked Phase IB Study Evaluating the Safety and Antiviral Activity of Aprepitant, a Neurokinin-1 Receptor Antagonist in HIV-1 Infected Adults

(2011) Pablo Tebas et al.   PLoS One

Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals

(2010) Mark M Manak et al.   AIDS

Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation

(2010) Steven D. Douglas et al.   Annals of the New York Academy of Sciences

Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor

(2010) Linda Monaco-Shawver et al.   JOURNAL OF LEUKOCYTE BIOLOGY

HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study

(2010) R. K. Heaton et al.   NEUROLOGY

Neurokinin-1 Receptor Expression and Function in Human Macrophages and Brain

(2009) Steven D. Douglas et al.   Annals of the New York Academy of Sciences

Neurokinin 1 receptor isoforms and the control of innate immunity

(2009) Florin Tuluc et al.   TRENDS IN IMMUNOLOGY

Short Communication: Elevated Substance P Levels in HIV-Infected Women in Comparison to HIV-Negative Women

(2008) Steven D. Douglas et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research

(2008) Di Wu et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Selective Serotonin Reuptake Inhibitor and Substance P Antagonist Enhancement of Natural Killer Cell Innate Immunity in Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome

(2007) Dwight L. Evans et al.   BIOLOGICAL PSYCHIATRY